X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GLENMARK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GLENMARK PHARMA PANACEA BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x 145.3 14.3 1,017.7% View Chart
P/BV x 3.2 3.8 85.6% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GLENMARK PHARMA
Mar-17
PANACEA BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs149993 15.0%   
Low Rs82729 11.3%   
Sales per share (Unadj.) Rs84.1325.5 25.8%  
Earnings per share (Unadj.) Rs-18.339.3 -46.6%  
Cash flow per share (Unadj.) Rs-6.748.7 -13.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7159.2 52.6%  
Shares outstanding (eoy) m61.25282.17 21.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.42.6 51.9%   
Avg P/E ratio x-6.321.9 -28.8%  
P/CF ratio (eoy) x-17.217.7 -97.4%  
Price / Book Value ratio x1.45.4 25.5%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m7,074242,991 2.9%   
No. of employees `0002.813.0 21.2%   
Total wages/salary Rs m1,44916,408 8.8%   
Avg. sales/employee Rs Th1,874.17,083.9 26.5%   
Avg. wages/employee Rs Th527.01,265.4 41.6%   
Avg. net profit/employee Rs Th-407.7855.1 -47.7%   
INCOME DATA
Net Sales Rs m5,15491,857 5.6%  
Other income Rs m100374 26.7%   
Total revenues Rs m5,25492,230 5.7%   
Gross profit Rs m-76620,367 -3.8%  
Depreciation Rs m7112,644 26.9%   
Interest Rs m1,5032,373 63.3%   
Profit before tax Rs m-2,88115,724 -18.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-810 -218.8%   
Tax Rs m173,827 0.4%   
Profit after tax Rs m-1,12111,088 -10.1%  
Gross profit margin %-14.922.2 -67.1%  
Effective tax rate %-0.624.3 -2.4%   
Net profit margin %-21.812.1 -180.3%  
BALANCE SHEET DATA
Current assets Rs m3,81068,746 5.5%   
Current liabilities Rs m8,36527,027 31.0%   
Net working cap to sales %-88.445.4 -194.6%  
Current ratio x0.52.5 17.9%  
Inventory Days Days15685 183.2%  
Debtors Days Days6796 70.4%  
Net fixed assets Rs m14,48024,132 60.0%   
Share capital Rs m61282 21.7%   
"Free" reserves Rs m90344,643 2.0%   
Net worth Rs m5,12744,925 11.4%   
Long term debt Rs m5,83245,363 12.9%   
Total assets Rs m19,433117,639 16.5%  
Interest coverage x-0.97.6 -12.0%   
Debt to equity ratio x1.11.0 112.6%  
Sales to assets ratio x0.30.8 34.0%   
Return on assets %2.011.4 17.2%  
Return on equity %-21.924.7 -88.6%  
Return on capital %3.619.1 19.0%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53956,152 2.7%   
Fx outflow Rs m9428,084 11.7%   
Net fx Rs m59748,068 1.2%   
CASH FLOW
From Operations Rs m5996,574 9.1%  
From Investments Rs m-438-7,124 6.1%  
From Financial Activity Rs m-3035,432 -5.6%  
Net Cashflow Rs m-1411,992 -7.1%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 6.9 8.7%  
FIIs % 1.3 34.4 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 56,727 18.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 19, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - GSK PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS